Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03431896 · ClinicalTrials.gov registry record
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
A clinical trial of Amyloidosis and AL Amyloidosis, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- 37
- Enrollment target
- 1
- Study location
NCT03431896: Completed study of Amyloidosis and AL Amyloidosis, sponsored by The Cleveland Clinic.
NCT03431896 is a study of Amyloidosis and AL Amyloidosis that has completed, run by The Cleveland Clinic. The registered enrollment target is 37 participants, below the 1,128-participant average among 28 other Amyloidosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03431896, a study of Amyloidosis and AL Amyloidosis, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
This study measures circulating, misfolded ATTR oligomers in asymptomatic ATTRm amyloidosis genetic carriers longitudinally over five years.
Primary Outcome
Change (%) for oligomer level at the time of TTR amyloid symptoms compared to baseline
Conditions Studied
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2026-03-09 |
What the finished NCT03431896 record still lists
NCT03431896 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 1,128-participant average among 28 other Amyloidosis trials with a reported enrollment target (97% lower).
The record links to 7 conditions, with Amyloidosis appearing as the primary indexed condition, and to 0 interventions.
NCT03431896 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03431896 about?
NCT03431896 is a clinical study titled "Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis". This study measures circulating, misfolded ATTR oligomers in asymptomatic ATTRm amyloidosis genetic carriers longitudinally over five years.
What is the current status of trial NCT03431896?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2018-02-01. Estimated completion is 2026-03-09.
What conditions does trial NCT03431896 study?
This clinical trial studies the following conditions: Amyloidosis, AL Amyloidosis, Transthyretin Amyloidosis, Amyloid Cardiomyopathy, Amyloid.
Who is sponsoring clinical trial NCT03431896?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03431896 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03431896's enrollment target sits among peer trials
37 20th of 28 higher than 8 of 28 other Amyloidosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyloidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
RECRUITING · Phase 2
-
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
RECRUITING
-
A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography
RECRUITING
-
Dietary Reporting in the Amyloidoses
RECRUITING · NA
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
-
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI